Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.

NCT03469050 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

193

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Diverticulitis

Interventions

DRUG: Rifaximin delayed released 400mg Tablet
OTHER: Placebo

Sponsor

Alfasigma S.p.A.